Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA

VOLUNTARY ANNOUNCEMENT - ENLONSTOBART INJECTION OBTAINS CONDITIONAL MARKETING APPROVAL GRANTED BY NMPA

June 28, 2024

恩朗苏拜单抗注射液获国家药品监督管理局附条件批准上市_00.png

恩朗苏拜单抗注射液获国家药品监督管理局附条件批准上市_01.png

Previous: CSPC Listed in 2023 Top 100 Chinese Chemical Pharmaceutical Enterprises

Next: VOLUNTARY ANNOUNCEMENTFIRST mRNA-LNP-BASED CAR-T CELL INJECTION (SYS6020)OBTAINS CLINICAL TRIAL APPROVAL

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat